This Article Abstract Free Full Text (Free PDF) Free Alert me when this article is cited Alert me if a correction is posted Citation Map Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Add to Saved Citations Download to citation manager Request Permissions Request Reprints Add to My Marked Citations Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Citing Articles via Scopus Google Scholar Articles by Schwarz, M. Articles by Buchmann, A. Search for Related Content PubMed PubMed Citation Articles by Schwarz, M. Articles by Buchmann, A. Social Bookmarking                         What's this?

Role of Connexin32 and β-Catenin in Tumor Promotion in Mouse Liver

Institut für Pharmakologie und Toxikologie, Universität Tübingen, Tübingen, Germany, michael.schwarz{at}uni-tuebingen.de

Ines Wanke

Institut für Pharmakologie und Toxikologie, Universität Tübingen, Tübingen, Germany

Ulrich Wulbrand

Institut für Pharmakologie und Toxikologie, Universität Tübingen, Tübingen, Germany

Oliver Moennikes

Institut für Pharmakologie und Toxikologie, Universität Tübingen, Tübingen, Germany

Albrecht Buchmann

Institut für Pharmakologie und Toxikologie, Universität Tübingen, Tübingen, Germany

Tumor promoters are nonmutagenic chemicals that increase the probability of cancer by accelerating the clonal expansion of cells transformed during tumor initiation. The molecular mechanisms underlying this process are only partly understood but interference with signaling pathways regulating cell division and/or cell death is likely to be important. Ras- and β-Catenin-dependent signaling is important for both of these processes and ras and β-catenin genes are known mutational targets in mouse hepatocarcinogenesis. About 80% of liver tumors generated in mice by a promotional regimen including phenobarbital (PB) as tumor promoter and N-nitrosodiethylamine (DEN) as initiator showed β-catenin mutations whereas Ha-ras mutations were not detected. By contrast, tumors from mice treated with DEN alone showed a ~30% Ha-ras mutation prevalence but no β-catenin mutations. This result suggests that PB-mediated promotion in mouse liver consists in a positive selection for hepatocytes harboring mutations in β-catenin. The gap junction protein connexin 32 (Cx32) was also found to be involved in tumor promotion by PB because Cx32 gene knockout mice were almost entirely resistent to the promotional effects of the barbiturate. The link between β-catenin-signaling and Cx32-dependent gap junctional intercellular communication, if existent, remains obscure.

Key Words: Mouse hepatocarcinogenesis • tumor promotion • phenobarbital • beta-catenin • Ha-ras • connexin32.

References

• Aydinlik H., Nguyen TD, Moennikes O., Buchmann A., Schwarz M. (2001). Selective pressure during tumor promotion by phenobarbital leads to clonal outgrowth of β-catenin-mutated mouse liver tumors. Oncogene 20: 7812— 7816.
• Bai S., Spray DC, Burk RD ( 1993). Identification of proximal and distal regulatory elements of the rat connexin32 gene. Biochim Biophys Acta 1216: 197—204.[Medline] [Order article via Infotrieve]
• Buchmann A., Bauer-Hofmann R., Mahr J., Drinkwater NR, Luz A., Schwarz M. (1991). Mutational activation of the c-Ha-ras gene in liver tumors of different rodent strains: Correlation with susceptibility to hepatocarcinogenesis. Proc Natl Acad Sci USA 88: 911—915.[Abstract/Free Full Text]
• Budunova IV, Williams GM (1994). Cell culture assays for chemicals with tumor-promoting or tumor-inhibiting activity based on the modulation of intercellular communication. Cell Biol Toxicol 10: 71—116.[CrossRef][Web of Science][Medline] [Order article via Infotrieve]
• de-La-Coste A., Romagnolo B., Billuart P., Renard CA, Buendia MA, Soubrane O., Fabre M., Chelly J., Beldjord C., Kahn A., Perret C. (1998). Somatic mutations of the β-catenin gene are frequent in mouse and human hepatocellular carcinomas. Proc Natl Acad Sci USA 95: 8847—8851.[Abstract/Free Full Text]
• Devereux TR, Anna CH, Foley JF, White CM, Sills RC, Barrett JC (1999). Mutation of β-catenin is an early event in chemically induced mouse hepatocellular carcinogenesis. Oncogene 18: 4726—4733.[CrossRef][Web of Science][Medline] [Order article via Infotrieve]
• Drinkwater NR, Bennet LM (1991). Genetic control of carcinogenesis in experimental animals. Prog Exp Tumor Res 33: 1—20.[Web of Science][Medline] [Order article via Infotrieve]
• Gebhardt R., Tanaka T., Williams G. (1989). Glutamine synthetase heterogeneous expression as a marker for the cellular lineage of preneoplastic and neoplastic liver populations. Carcinogenesis 10: 1917—1923.[Abstract/Free Full Text]
• Grasso P., Hardy J. (1975). Strain differences in natural incidence and response to carcinogens. In: Mouse Hepatic Neoplasia, Butler WH, Newberne PM (eds). Elsevier Scientific Publications Co, Amsterdam, Oxford, New York, pp 111—131.
• Honkakoski P., Negishi M. (2000). Regulation of cytochrome P450 (CYP) genes by nuclear receptors. Biochem J 347: 321—337.[CrossRef][Web of Science][Medline] [Order article via Infotrieve]
• Kamei Y., Xu L., Heinzel T., Torchia J., Kurokawa R., Gloss B., Lin SC, Heyman RA, Rose DW, Glass CK, Rosenfeld MG (1996). A CBP integrator complex mediates transcriptional activation and AP-1 inhibition by nuclear receptors. Cell 85: 403—414.[CrossRef][Web of Science][Medline] [Order article via Infotrieve]
• Korinek V., Barker N., Morin PJ, van-Wichen D., de-Weger R., Kinzler KW, Vogelstein B., Clevers H. (1997). Constitutive transcriptional activation by a beta-catenin-Tcf complex in APC-/- colon carcinoma. Science 275: 1784—1787.[Abstract/Free Full Text]
• Loeppen S., Schneider D., Gaunitz F., Gebhardt R., Kurek R., Buchmann A., Schwarz M. (2002). Overexpression of glutamine synthetase is associated with β-catenin-mutations in mouse liver tumors during promotion of hepatocarcinogenesis by phenobarbital. Cancer Res 62: 5685—5688.[Abstract/Free Full Text]
• Maronpot RR, Fox T., Malarkey DE, Goldsworthy TL (1995) Mutations in the ras proto-oncogene: Clues to etiology and molecular pathogenesis of mouse liver tumors. Toxicology 101: 125—156.[CrossRef][Web of Science][Medline] [Order article via Infotrieve]
• Moennikes O., Buchmann A., Ott T., Willecke K., Schwarz M. (1999). The effect of connexin32 null mutation on hepatocarcinogenesis in different mouse strains. Carcinogenesis 20: 1379—1382.[Abstract/Free Full Text]
• Moennikes O., Buchmann A., Romualdi A., Ott T., Werringloer J., Willecke K., Schwarz M. (2000). Lack of phenobarbital mediated promotion of hepatocarcinogenesis in connexin32 null mice. Cancer Res 60: 5087—5091.[Abstract/Free Full Text]
• Parkin DM, Bray FI, Devesa SS (2001) Cancer burden in the year 2000. The global picture. Eur J Cancer 37(Suppl 8): S4—S66.[Web of Science][Medline] [Order article via Infotrieve]
• Polakis, P. (2000). Wnt signaling and cancer. Genes Dev 14: 1837—1851.[Free Full Text]
• Schwarz M., Buchmann A., Stinchcombe S., Luebeck G., Moolgavkar S., Bock KW ( 1995). Role of receptors in human and rodent hepatocarcinogenesis. Mutat Res 333: 69—79.[CrossRef][Web of Science][Medline] [Order article via Infotrieve]
• Swierenga SH, Yamasaki H. (1992). Performance of tests for cell transformation and gap-junctional intercellular communication for detecting nongenotoxic carcinogenic activity. In: Mechanisms of Carcinogenesis in Risk Identification, No. 116, Vainio H, Maggee P, McGregor D, McMichael AJ (eds). IARC Scientific Publications, Lyon, pp 165—193.
• Temme A., Buchmann A., Gabriel HD, Nelles E., Schwarz M., Willecke K. (1997). High incidence of spontaneous and chemically induced liver tumors in mice deficient for connexin32. Curr Biol 7: 713—716.[CrossRef][Web of Science][Medline] [Order article via Infotrieve]
• Trosko JE, Ruch RJ ( 1998). Cell-cell communication in carcinogenesis. Frontiers Biosci 3: 208—236.
• van der Heyden MA, Rook MB, Hermans MM, Rijksen G., Boonstra J., Defize LH, Destree OH (1998). Identification of connexin43 as a functional target for Wnt signalling. J Cell Sci 111: 1741—1749.[Abstract]
• Yamasaki H., Naus CC (1996). Role of connexin genes in growth control. Carcinogenesis 17: 1199—1213.[Free Full Text]

Toxicologic Pathology, Vol. 31, No. 1, 99-102 (2003)
DOI: 10.1080/01926230390173932


CiteULike    Complore    Connotea    Del.icio.us    Digg    Reddit    Technorati    Twitter    What's this?

This article has been cited by other articles:

				G. Prost, F. Bernier-Valentin, M. Croset, and B. Rousset Impact of connexin32 deletion on E7 or RET/PTC3 oncogene-driven growth and neoplastic transformation of the thyroid gland Endocr. Relat. Cancer, September 1, 2009; 16(3): 873 - 884. [Abstract] [Full Text] [PDF]

				J. M. Phillips, L. D. Burgoon, and J. I. Goodman Phenobarbital Elicits Unique, Early Changes in the Expression of Hepatic Genes that Affect Critical Pathways in Tumor-Prone B6C3F1 Mice Toxicol. Sci., June 1, 2009; 109(2): 193 - 205. [Abstract] [Full Text] [PDF]

This Article Abstract Free Full Text (Free PDF) Free Alert me when this article is cited Alert me if a correction is posted Citation Map Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Add to Saved Citations Download to citation manager Request Permissions Request Reprints Add to My Marked Citations Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Citing Articles via Scopus Google Scholar Articles by Schwarz, M. Articles by Buchmann, A. Search for Related Content PubMed PubMed Citation Articles by Schwarz, M. Articles by Buchmann, A. Social Bookmarking                         What's this?